Fresenius SE & Co KGaA
XHAN:FRE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fresenius SE & Co KGaA
XHAN:FRE
|
DE |
Intrinsic Value
The intrinsic value of 
Fresenius SE & Co KGaA (FRE) under the Base Case is 50.66 EUR per share.
Compared with the current market price of 46.34 EUR, the stock appears
Undervalued by 9% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Fresenius SE & Co KGaA Does
Fresenius SE & Co KGaA is a healthcare company that makes medical products and runs hospitals. Its product side, Fresenius Kabi, sells things like IV fluids, injectable medicines, clinical nutrition products, infusion pumps, and other supplies used in hospitals and clinics. Its hospital side treats patients through large hospital networks in Germany and Spain, where it provides inpatient care, surgeries, and related medical services.
- Headquarters
- Germany DE
- Employees
- 316 078
- IPO date
- Dec 18, 1986
Fresenius SE & Co KGaA has no economic moat
Competing suppliers offer alternatives to many Fresenius medicines and hospital products, while other hospital operators compete for its patients. Its size and reputation help it compete, but do not give it lasting control over customers or prices.
Read the full moat analysis
Revenue & Expenses Breakdown
Fresenius SE & Co KGaA
Earnings Waterfall
Fresenius SE & Co KGaA
The intrinsic value for Fresenius SE & Co KGaA (FRE) under the Base Case is 50.66 EUR.
Compared with the current market price of 46.34 EUR, the stock appears Undervalued by 9% .